European regulators greenlight AZ's Nexium combo

AstraZeneca's ($AZN) Nexium-plus-aspirin combo, dubbed Axanum, got the nod from European regulators. The company says it's working to get the drug onto formularies there as soon as possible. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.